Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September
James Brumley, The Motley Fool
Fri, September 11, 2026 at 12:35 PM GMT+3 4 min read
Given that the beginning of 2027 is now less than four months away, it wouldn't be wrong to begin positioning your portfolio for the coming year.
To this end, here's a closer look at two pharmaceutical stocks, each with a handful of developments and/or milestones already lined up that could be -- and should be -- bullish.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
CRISPR Therapeutics
When CRISPR Therapeutics (NASDAQ: CRSP) first won FDA approval for its gene-editing sickle cell disease treatment Casgevy back in late 2023, it was seemingly ready to launch with marketing partner Vertex Pharmaceuticals. Now, nearly three years later, there's still minimal Casgevy revenue being generated, and, technically, no reported generally accepted accounting principles (GAAP) revenue from drug sales.
Don't be discouraged, though. It's coming, beginning in earnest next year.
The seemingly slow start reflects how Casgevy is administered and when its revenue is officially recorded by CRISPR. See, since each treatment is custom-created for that particular patient, it can take roughly a year to complete the treatment regimen. And that's after a patient has been identified and approved as an eligible candidate for the drug, which can take a while as well.
Moreover, CRISPR Therapeutics doesn't officially book revenue until the entire treatment process is complete and the treatment is billed, with CRISPR's share then collected from Vertex. The whole process can take a while.
It's brewing, though. While it's done CRISPR no fiscal good yet, the $76 million worth of Casgevy revenue that Vertex facilitated in Q2 is a 78% year-over-year improvement and a clear acceleration from Q1's figure of $43 million.
Analysts are looking for this ongoing sales growth to finally start benefiting CRISPR Therapeutics in earnest in 2027, projecting the company's reported revenue to expand from just over $40 million this year to over $156 million next year. That should get investors' attention, making the biopharma company a very real contender.
Viking Therapeutics
The other drugmaker with bullish catalysts in the cards for 2027 is Viking Therapeutics (NASDAQ: VKTX).
Simply put, Viking Therapeutics is entering the crowded GLP-1 weight-loss drug market, but with a twist. Rather than the weekly injections that more familiar options like Eli Lilly's Zepbound and Novo Nordisk's Wegovy require, Viking's VK2735 shows strong promise as a more convenient monthly maintenance injection. The company also expects to begin late-stage trials of the same weight-loss drug in an orally administered pill format before the end of this year.
VK2735 has not been approved by any regulatory body in any form yet, to be clear. But that's somewhat the point -- its clinical trial results thus far have been encouraging, setting the stage for more good news in the year ahead as the company posts developmental progress for the GLP-1 weight loss drug. The fact that shares have been in a lethargic funk for nearly a year now only bolsters their potential upside as that news moves VK2735 closer to what are hopefully multiple approvals.
Analysts are on board anyway. Nearly all of them covering this stock currently rate VKTX a strong buy, with a consensus 12-month price target of $93.11, which is 175% above the ticker's present price.
Should you buy stock in CRISPR Therapeutics right now?
Before you buy stock in CRISPR Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $410,024!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,372,815!*
Now, it's worth noting Stock Advisor's total average return is 950% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of September 11, 2026.
James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals. The Motley Fool recommends CRISPR Therapeutics and Viking Therapeutics. The Motley Fool has a disclosure policy.
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September was originally published by The Motley Fool
Yorumlar (0)
Giriş yaparak yorum yazabilirsin.
İlk yorumu sen yaz.